Stock Price Updates, Appointment, and Financial Results - Analyst Notes on Regeneron, DENTSPLY, AMAG, Cadence, and ArthroCare

  Stock Price Updates, Appointment, and Financial Results - Analyst Notes on
              Regeneron, DENTSPLY, AMAG, Cadence, and ArthroCare

Editor Note: For more information about this release, please scroll to bottom.

PR Newswire

NEW YORK, March 6, 2014

NEW YORK, March 6, 2014 /PRNewswire/ --

Today, Analysts Review released its analysts' notes regarding Regeneron
Pharmaceuticals, Inc. (NASDAQ: REGN), DENTSPLY International Inc. (NASDAQ:
XRAY), AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG), Cadence Pharmaceuticals Inc.
(NASDAQ: CADX), and ArthroCare Corporation (NASDAQ: ARTC). Private wealth
members receive these notes ahead of publication. To reserve complementary
membership, limited openings are available at:
http://www.AnalystsReview.com/register

--

Regeneron Pharmaceuticals, Inc. Analyst Notes

On February 27, 2014, Regeneron Pharmaceuticals, Inc.'s (Regeneron) stock
increased 0.61%, ending the day at $338.54. Over the previous three trading
sessions, shares of Regeneron declined 2.61%, compared to the Nasdaq Composite
Index which increased 0.60% during the same period. The full analyst notes on
Regeneron Pharmaceuticals, Inc. are available to download free of charge at:

http://www.AnalystsReview.com/03062014/REGN/report.pdf

--

DENTSPLY International Inc. Analyst Notes

On February 18, 2014, DENTSPLY International Inc. (DENTSPLY) reported its
financial results for Q4 2013 and 2013. Q4 2013 net sales remained flat at
$753.7 million on a year-on-year basis, while the same gained 0.8% YoY to
$2.95 billion in 2013. Net income attributable to DENTSPLY for Q4 2013 was
$74.4 million, or $0.51 per diluted share, versus $126.8 million, or $0.88 per
diluted share, in Q4 2012. For 2013, net income attributable to DENTSPLY stood
at $313.2 million or $2.16 per diluted share, compared with $314.2 million or
$2.18 per diluted share in 2012. Bret Wise, Chairman and CEO, commented, "We
continue to be pleased with the progress we have made in accelerating earnings
growth over the past few quarters, as we realize benefits from our integration
and cost savings activities. Looking ahead, we see opportunities to continue
to drive market share growth across our global portfolio by leveraging our
core strategies of innovation, clinical education and sales force
effectiveness. We believe that global market conditions will improve slightly
in 2014 and, accordingly, we are expecting adjusted earnings in the range of
$2.45 to $2.55 per share, representing growth in the range of 4% to 9% for the
year." The full analyst notes on DENTSPLY International Inc. are available to
download free of charge at:

http://www.AnalystsReview.com/03062014/XRAY/report.pdf

--

AMAG Pharmaceuticals, Inc. Analyst Notes

On February 25, 2014, AMAG Pharmaceuticals, Inc. (AMAG) announced the
appointment of Edward Jordan as Senior Vice President of sales and marketing.
William Heiden, President and CEO of AMAG, commented, "I have known Ed for
many years, and am confident that, with his deep experience in pharmaceutical
and device commercial leadership, he will be a great addition to our executive
team. Ed's ability to build and lead top-performing commercial teams will be a
great asset to AMAG as we continue to drive market share growth and market
expansion for our current products." Jordan added, "I am very pleased to be
joining AMAG. It is an exciting time; coming off such a successful 2013 and
well positioned for significant growth and success. I look forward to leading
the commercial team and contributing to the company's goals of continuing to
grow Feraheme and MuGard sales, expanding the product portfolio and building a
multi-product, profitable specialty pharmaceutical company." The full analyst
notes on AMAG Pharmaceuticals, Inc. are available to download free of charge
at:

http://www.AnalystsReview.com/03062014/AMAG/report.pdf

--

Cadence Pharmaceuticals Inc. Analyst Notes

On February 27, 2014, Cadence Pharmaceuticals Inc.'s (Cadence) stock increased
0.14%, ending the day at $14.02. Over the previous three trading sessions,
shares of Cadence increased 0.36%, compared to the Nasdaq Composite Index
which increased 0.60% during the same period. The full analyst notes on
Cadence Pharmaceuticals Inc. are available to download free of charge at:

http://www.AnalystsReview.com/03062014/CADX/report.pdf

--

ArthroCare Corporation Analyst Notes

On February 27, 2014, ArthroCare Corporation's (ArthroCare) stock increased
0.04%, ending the day at $48.28. Over the previous three trading sessions,
shares of ArthroCare declined 0.35%, compared to the Nasdaq Composite Index
which increased 0.60% during the same period. The full analyst notes on
ArthroCare Corporation are available to download free of charge at:

http://www.AnalystsReview.com/03062014/ARTC/report.pdf

--

About Analysts Review
We provide our members with a simple and reliable way to leverage our economy
of scale. Most investors do not have time to track all publicly traded
companies, much less perform an in-depth review and analysis of the
complexities contained in each situation. That's where Analysts Review comes
in. We provide a single unified platform for investors' to hear about what
matters. Situation alerts, moving events, and upcoming opportunities.

--

=============

EDITOR NOTES:

  oThis is not company news. We are an independent source and our views do
    not reflect the companies mentioned.
  oInformation in this release is fact checked and produced on a best efforts
    basis and reviewed by Nidhi Vatsal, a CFA charterholder. However, we are
    only human and are prone to make mistakes. If you notice any errors or
    omissions, please notify us below.
  oThis information is submitted as a net-positive to companies mentioned, to
    increase awareness for mentioned companies to our subscriber base and the
    investing public.
  oIf you wish to have your company covered in more detail by our team, or
    wish to learn more about our services, please contact us at pubco [at]
    AnalystsReview.com.
  oFor any urgent concerns or inquiries, please contact us at compliance [at]
    AnalystsReview.com.
  oAre you a public company? Would you like to see similar coverage on your
    company? Send us a full investors' package to research [at]
    AnalystsReview.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Analysts Review. An
outsourced research services provider represented by Nidhi Vatsal, CFA, has
only reviewed the information provided by Analysts Review in this article or
report according to the Procedures outlined by Analysts Review. Analysts
Review is not entitled to veto or interfere in the application of such
procedures by the outsourced provider to the articles, documents or reports,
as the case may be.

NOT FINANCIAL ADVICE

Analysts Review makes no warranty, expressed or implied, as to the accuracy or
completeness or fitness for a purpose (investment or otherwise), of the
information provided in this document. This information is not to be construed
as personal financial advice. Readers are encouraged to consult their personal
financial advisor before making any decisions to buy, sell or hold any
securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Analysts Review is not responsible for any error which may be occasioned at
the time of printing of this document or any error, mistake or shortcoming. No
liability is accepted by Analysts Review whatsoever for any direct, indirect
or consequential loss arising from the use of this document. Analysts Review
expressly disclaims any fiduciary responsibility or liability for any
consequences, financial or otherwise arising from any reliance placed on the
information in this document. Analysts Review does not (1) guarantee the
accuracy, timeliness, completeness or correct sequencing of the information,
or (2) warrant any results from use of the information. The included
information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA
Institute.

http://AnalystsReview.com



SOURCE Analysts Review

Contact: Adam Redford, +852-8191-3972
 
Press spacebar to pause and continue. Press esc to stop.